2013-024 Resolution of the 12th Board of Directors of Jianfeng Group
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviations: Jianfeng Group Number: pro 2013-024
Zhejiang Jianfeng Group Co., Ltd. 12th Board of Directors Resolution Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
On August 2, 2013, Zhejiang Jianfeng Group Co., Ltd. issued the convening of the 8th Board of Directors by fax, e-mail, telephone , and personal delivery. The notice of the 12 th meeting, this meeting was held by a combination of on-site and communication. On August 14, 2013, the on-site meeting was held as scheduled in the conference room of Zhejiang Jinhua Jianfeng Building. Five people attended the on-site meeting. Four foreign directors Huang Sujian, Deng Mingran, Liu Jiajian and Zhang Yuyou voted by fax. The on-site meeting was presided over by Chairman Jiang Xiaomeng, and supervisors and senior managers of Company attended the meeting as nonvoting delegates, in accordance with the relevant regulations of the Company Law and the Articles of Association of the Company , the resolution made is legal and valid. After deliberation and voting, the following resolution was adopted:
1. 2013 semi-annual report After deliberation and voting, the board of directors adopted the 2013 semi-annual report of the company. Voting result: 9 votes in favor, 0 votes against and 0 abstentions. 2. Proposal on Jianfeng Pharmaceutical to Set up a Joint Venture to Cooperate in Developing New Drugs After deliberation and voting, the board of directors passed the proposal, agreeing that Jianfeng Pharmaceutical should contribute 2090
yuan in monetary installments and Shanghai Hansheng Biotechnology Co., Ltd. should contribute 1710 yuan in patented technology intellectual property rights to set up a joint venture, carry out research, development and operation of new anti-tumor drugs (YLK ). It is also agreed that Jianfeng Pharmaceutical will pay Shanghai Hansheng Biotechnology Co., Ltd. 400 yuan in cash compensation for early research and development in installments .
Voting result: 9 votes in favor, 0 votes against, 0 abstentions. After deliberation and voting on the 3.'s related party transaction proposal on the acquisition of the equity of peak cement, the board of directors passed the related party transaction proposal, agreeing that the company should acquire the 1.34 equity of Zhejiang peak cement co., ltd.
held by Jinhua peak union investment co., ltd. at a price of of 8.71 million yuan. Jiang Xiaomeng, Du Zihong and Yu Jianhong, directors of Guan of the company, avoided voting on the bill.
voting result: 6 votes in favor, 0 votes against, 0 votes abstained. For details, please refer to the Announcement of Related Transactions on the Acquisition of Equity Interest in Peak Cement (P.91 2013-025 ).
hereby announces
August 16, 2013
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page